136109 20260217205550.0 doi 10.1111/bcp.16157 sideral 139065 ART-2024-139065 eng Vinuesa-Hernando, José Manuel Initiation of lipid-lowering therapy as primary prevention of cardiovascular disease in the elderly 2024 Access copy available to the general public Unrestricted Aims This study aimed to analyse the initiation adherence phase to lipid-lowering therapy for primary prevention of cardiovascular disease in a Spanish population aged 70 years or older. The secondary objective was to identify the determinants of initiation and early discontinuation. Methods This was an observational study conducted in the CArdiovascular Risk factors for HEalth Service research (CARhES) cohort. People aged 70 and older with a first prescription of a lipid-lowering drug and without a previous major adverse cardiovascular event (MACE) were selected (2018–2021). Data on sociodemographics, clinical conditions, drugs and use of health services were collected from clinical and administrative electronic databases. The study population was classified into: non-initiation, early discontinuation (i.e., discontinuation after the first dispensing) and initiation with more than one dispensing. Their characteristics were compared. Determinants of initiation and early discontinuation were explored. Results Among the 15 019 people studied, 80.2% initiated the medication, 11.2% showed an early discontinuation and 8.6% were non-initiators. An older age or conditions such as dementia, diabetes or depression reduced the likelihood of initiation, while obesity and a high pharmacological burden increased it. People over 90 years of age or those prescribed a statin in combination were more likely to have an early discontinuation. Conclusions Non-initiation and early discontinuation are common among older people prescribed lipid-lowering drugs as primary prevention of cardiovascular disease for the first time. The presence of chronic pathologies other than cardiovascular ones should be considered when assessing whether or not to prescribe these drugs in the elderly. info:eu-repo/grantAgreement/ES/DGA-GRISSA/B09-23R info:eu-repo/grantAgreement/ES/ISCIII/PI22-01193 info:eu-repo/semantics/openAccess by-nc https://creativecommons.org/licenses/by-nc/4.0/deed.es 3.0 2024 PHARMACOLOGY & PHARMACY 138 / 352 = 0.392 2024 Q2 T2 1.155 2024 Pharmacology (medical) 2024 Q1 Pharmacology 2024 Q1 7.2 2024 info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion Aguilar-Palacio, Isabel Universidad de Zaragoza (orcid)0000-0001-7293-701X Rabanaque, María José Universidad de Zaragoza (orcid)0000-0002-6671-5661 García-Cárdenas, Victoria Lallana, María Jesús Gamba, Adriana Malo, Sara Universidad de Zaragoza (orcid)0000-0002-7194-8275 1011 615 Universidad de Zaragoza Dpto. Microb.Ped.Radio.Sal.Pú. Área Medic.Prevent.Salud Públ. 90, 10 (2024), 2663-2672 Br. j. clin. pharmacol. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY 0306-5251 997330 http://zaguan.unizar.es/record/136109/files/texto_completo.pdf Versión publicada 2223456 http://zaguan.unizar.es/record/136109/files/texto_completo.jpg?subformat=icon icon Versión publicada oai:zaguan.unizar.es:136109 articulos driver 2026-02-17-20:39:56 ARTICLE